Micronized / ultramicronized palmitoylethanolamide (PEA) as natural neuroprotector against COVID-19 inflammation
ReviewHumans
- Design
- Review
- Subjects
- A mini-review plus one 45-year-old woman with COVID-19
- Dose used in the study
- Micronised and ultramicronised palmitoylethanolamide; dose not stated in the abstract
- Duration
- Not stated in the abstract
- What was measured
- Why phospholipid intake and possible secondary antiphospholipid syndrome matter in COVID-19, illustrated with a single case report of PEA use
What the authors reported
One 45-year-old woman with COVID-19 was, in the authors' words, treated with success using micronised and ultramicronised PEA. The review also sets out PEA's anti-inflammatory and neuroprotective properties. No outcome measures, dose or timing are given in the abstract.
Limits of this study
A narrative review with a single uncontrolled case, no dose and no outcome data in the abstract; it cannot show that PEA affected COVID-19. The authors declare no competing interest.
Source
PubMed 33636368 · doi:10.1016/j.prostaglandins.2021.106540
Entry checked against the abstract on PubMed on 2026-09-22. The dose shown is the dose the researchers used. It is not a recommendation. How to read this page.